WHAT THE HECK IS A DPD DEFICIENCY?

Stage IV survivor and advocate Kathy Oliver enjoys living in beautiful Huntington Beach, California. She was diagnosed with colon cancer in 2012 and is surviving and thriving in spite of her disease. Her motto is “knowledge is power” and her mission is to help fellow…

Read Full Post

Ramucirumab – A New Treatment Option

The FDA approved the use of the drug ramucirumab (brand name Cyramza®) on April 24, 2015 for patients with metastatic colorectal cancer in combination with FOLFIRI. Ramucirumab with FOLFIRI is now approved for patients whose cancer has progressed during or after treatment with first line…

Read Full Post

Another treatment option coming down the pike: TAS-102

Fight Colorectal Cancer stays actively involved in the research process from beginning to end. Part of our role in research is monitoring the progress of new drugs – drugs that may be used in treatment plans of colorectal cancer in the future. We actively work…

Read Full Post

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in…

Read Full Post

July 2012 Webinar: Treating Late Stage Colorectal Cancer

Dr. Leonard Saltz of the Memorial Sloan-Kettering Cancer Center explains what treatment options exist for patients with late stage disease. Unfortunately, far too many patients will still hear their doctors say, “We are running out of options.” Fight Colorectal Cancer Director of Patient Information Services…

Read Full Post

Highlights from ASCO 2011

While there weren’t new blockbuster announcements for colorectal cancer this year at the American Society for Clinical Oncology’s (ASCO) Annual Meeting, there was plenty of focus on making what we already have work better and on choosing the patients who will benefit the most from…

Read Full Post